Fasigyn

• Angiotensin-Converting Enzyme Inhibitors
• Antihypertensive Agents
• ATC:C09AA10

• Fasigyn
• Tindamax

• No information avaliable

C₂₄H₃₄N₂O₅

http://www.rxlist.com/cgi/generic3/mavik.htm

Fasigyn MSDS

No information avaliable

430.537 g/mol

119-123^oC

No information avaliable

Solid

3.599

Capsule; Tablets (1 mg, 2 mg, or 4 mg of trandolapril for oral administration)

For the treatment of hypertension.

Trandolapril is the ethyl ester prodrug of a nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, trandolaprilat. Trandolapril is deesterified to the diacid metabolite, trandolaprilat, which is approximately eight times more active as an inhibitor of ACE activity. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. Angiotensin II is a potent peripheral vasoconstrictor that also stimulates secretion of aldosterone by the adrenal cortex and provides negative feedback for renin secretion.

Absolute bioavailability after oral administration of trandolapril is about 10% as trandolapril and 70% as trandolaprilat. Food slows absorption of trandolapril, but does not affect the area under the plasma concentration–time curve (AUC) or peak plasma concentration (C_max) of trandolaprilat or C_max of trandolapril.

No data are available with respect to overdosage in humans. The oral LD₅₀ of trandolapril in mice was 4875 mg/Kg in males and 3990 mg/Kg in females. In rats, an oral dose of 5000 mg/Kg caused low mortality (1 male out of 5; 0 females). In dogs, an oral dose of 1000 mg/Kg did not cause mortality and abnormal clinical signs were not observed. In humans the most likely clinical manifestation would be symptoms attributable to severe hypotension.

Humans and other mammals